Бібліотека Вінницького національного медичного університету ім. М.І.Пирогова

Главная

Упрощенный режим

Видео-инструкция

Описание

Базы данных

Периодические издания- результаты поиска

Вид поиска

Книги

Периодические издания

Область поиска

Формат представления найденных документов:
полный	информационный	краткий

Отсортировать найденные документы по:
автору	заглавию	году издания	типу документа

Поисковый запрос: <.>II=ЕУ12/2020/42/2<.>

Общее количество найденных документов : 13
Показаны документы с 1 по 13

Prognostic role of androgen receptor expression in patients with metastatic triple negative breast cancer / S. A. Lyalkin [et al.] // Experimental Oncology. - 2020. - Том 42, N 2. - P140-143

MeSH-главная:
МОЛОЧНОЙ ЖЕЛЕЗЫ НОВООБРАЗОВАНИЯ -- BREAST NEOPLASMS (диагностика, осложнения, патофизиология)
НОВООБРАЗОВАНИЙ МЕТАСТАЗЫ -- NEOPLASM METASTASIS (диагностика, патофизиология, терапия)
Аннотация: At present, there are no valid prognostic biomarkers in patients with triple negative breast cancer (TNBC) except well known clinical factors such as tumor size, lymph node status, differentiation grade and proliferation rate. Aim: To evaluate the prognostic role of androgen receptor (AR) expression in patients with TNBC. Materials and Methods: The effect of the AR expression level in tumor tissue on overall survival depending on clinical, histological and immunohistochemical characteristics of the tumor was evaluated in 116 patients with metastatic TNBC. Results: The independent prognostic value of AR expression in patients with TNBC of different stages was shown. The median overall survival was higher in patients with AR-positive tumors compared with AR-negative tumors (57 months vs 27 months, p 0.0001). Five-year survival since diagnosis in the group with AR-positive TNBC was 47.6 ± 8.3% vs 20.0 ± 5.3% in the group with AR-negative TNBC (p 0.05). Conclusions: The results of our study indicate a favorable impact of AR expression on the overall survival of TNBC patients
Доп.точки доступа:
Lyalkin, S. A.
Verevkina, N. O.
Alekseyenko, O. O.
Syvak, L. A.

Свободных экз. нет

Найти похожие

Pankaj, D.
Clinicopathological correlation of the expression of excision repair cross complementation group 1 (ERCC1) in oral cavity squamous cell carcinomas: an immunohistochemical study / D. Pankaj, V. Guddattu, M. C. Solomon // Experimental Oncology. - 2020. - Том 42, N 2. - P135-139

MeSH-главная:
КАРЦИНОМА ПЛОСКОКЛЕТОЧНАЯ -- CARCINOMA, SQUAMOUS CELL (патофизиология, терапия)
РОТОВОЙ ПОЛОСТИ НОВООБРАЗОВАНИЯ -- MOUTH NEOPLASMS (патофизиология, терапия)
Аннотация: The nucleotide excision repair pathway is a sophisticated DNA repair mechanism that reduces DNA damage caused by exogenous factors. Excision repair cross complementation group 1 (ERCC1) is a prominent member of this pathway that maintains the genomic stability. The aim of this study is to determine the association between the immunohistochemical expression of ERCC1 and the clinical and pathological features of oral cavity squamous cell carcinomas. Materials and Methods: The sections of formalin fixed paraffin embedded tissue blocks of oral squamous cell carcinomas (n = 60) were immunohistochemically stained with anti-ERCC1 antibody. The association between the nuclear expression of ERCC1 and the clinicopathological parameters of the tumors and the patient outcomes was evaluated using the chi-square test. Results: ERCC1 expression was evident in all studied cases of the oral squamous cell carcinomas. A high ERCC1 expression was associated with smaller tumors, tumors without lymph node involvement and well-differentiated tumors (p 0.001). Better outcomes were associated with higher expression of ERCC1 (p
Доп.точки доступа:
Guddattu, V.
Solomon, M. C.

Свободных экз. нет

Найти похожие

HRM screening of the UBC9 gene encoding the SUMO-E2-conjugating enzyme - case-control study in breast cancer / P. Bialik [et al.] // Experimental Oncology. - 2020. - Том 42, N 2. - P130-134

MeSH-главная:
МОЛОЧНОЙ ЖЕЛЕЗЫ НОВООБРАЗОВАНИЯ -- BREAST NEOPLASMS (генетика)
Аннотация: UBC9 (E2) small ubiquitin-like modifier conjugating enzyme plays a key role in the post-translational modification of proteins named sumoylation. Defects in small ubiquitin-like modifier modification may contribute to breast carcinogenesis. In the present work, we examined UBC9 genetic variation. Materials and Methods: UBC9 genetic variation was analyzed by using the high resolution melting (HRM) method. HRM study was conducted on 173–182 healthy women and 188–190 women with breast cancer. Results: During HRM screening, we analysed three known single-nucleotide polymorphisms in introns: rs4984806, rs909916 and rs909917, and one known single nucleotide polymorphism rs8063 in exon 7, in a non-coding region. The genotype frequencies for all polymorphisms were in accordance with Hardy — Weinberg equilibrium among the control subjects and breast cancer patients. The linkage disequilibrium analysis displayed that there was one polymorphism block, which consisted of three single nucleotide polymorphisms: rs909916, rs909917 and rs4984806. We identified two common haplotypes CCG and TTC, but we did not find significant differences in the distribution of these haplotypes between cases and controls. Conclusion: Our study showed no differences in the occurrence of indicated polymorphisms in the UBC9 gene in a group of healthy women compared to women with breast cancer. These results suggest that the polymorphisms of the UBC9 gene — rs4984806, rs909916, rs909917 and rs8063 can be not associated with breast cancer risk
Доп.точки доступа:
Bialik, P.
Wysokinski, D.
Slomka, M.
Morawiec, Z.
Strapagiel, D.
Wozniak, K.

Свободных экз. нет

Найти похожие

Kliusov, O. M.
Specialized care provided to patients with rectal cancer in Kyiv city / O. M. Kliusov // Experimental Oncology. - 2020. - Том 42, N 2. - P157-160

MeSH-главная:
ПРЯМОЙ КИШКИ НОВООБРАЗОВАНИЯ -- RECTAL NEOPLASMS (патофизиология, терапия, уход)
Аннотация: The major trends in the rectal cancer incidence, detectability, morbidity, and mortality in Kyiv city as well as the state of medical care organization for cancer patients based on the statistical data of Kyiv City Clinical Oncology Center were analyzed. Despite the decrease in morbidity (‒6.3%) and mortality (‒8.1%), the cohort of rectal cancer patients in Kyiv city is increasing (+18.2%). At the same time, one-year mortality (27.0% in 2017), the detection rate at preventive check-ups, the detection rates at the early (I–II) stages are decreasing and at late-stage (IV) are rising (from 14.9% in 2011 to 17.6% in 2017). The above indicates the need for improving the organization of medical care of cancer patients and early diagnostics of rectal cancer
Свободных экз. нет

Найти похожие

Temozolomide in glioblastoma treatment: 15-year clinical experience and analysis of its efficacy / O. Ya. Glavatskyi [et al.] // Experimental Oncology. - 2020. - Том 42, N 2. - P148-156

MeSH-главная:
ГЛИОБЛАСТОМА -- GLIOBLASTOMA (патофизиология, терапия)
МОЗГА ГОЛОВНОГО НОВООБРАЗОВАНИЯ -- BRAIN NEOPLASMS (патофизиология, терапия)
Аннотация: To analyze retrospectively the efficacy of temozolomide (TMZ) in various treatment regimens in glioblastoma patients accounting for varying parameters of their treatment. Materials and Methods: 302 glioblastoma patients were treated at the State Institution “Romodanov Institute of Neurosurgery of the National Academy of Medical Sciences of Ukraine” from 2003 through 2017. All the patients were surgically treated. In 205 patients, the surgery was followed by adjuvant radiotherapy (RT) with concomitant TMZ (RT + TMZ group). In 97 patients, the surgery was followed by adjuvant RT only (RT group). Kaplan — Meier survival analysis with log-rank test and Cox proportional hazards regression analysis were used for comparing overall survival (OS) and recurrence-free survival (RFS) depending on the age and gender of the patients, the extent of tumor resection, the chemotherapy intensity and the type of RT. Results: In RT + TMZ group as a whole, OS median was 20.7 months vs 10.8 months in RT group (р 0.0001). The RFS was 14.8 months vs 7.9 months, correspondingly (р 0.0001).The survival did not depend on the age, gender or localization of the tumor. On the contrary, the intensity of CTX (the number of TMZ cycles in adjuvant mode), the extent of tumor resection, and the type of RT were among the factors affecting significantly OS and RFS. The improvement in OS and RFS with increasing number of the maintenance TMZ courses was more significant in the patients aged below 60. The use of stereotactic conformal mode for RT provides an advantage in the survival over the conventional RT in RT + TMZ group. Conclusions: The combination of concomitant and adjuvant maintenance CTX with TMZ was the most effective CTX regimen affecting positively OS and RFS
Доп.точки доступа:
Glavatskyi, O. Ya.
Zemskova, O. V.
Khmelnytskyi, H. V.
Kardash, K. A.
Shuba, I. M.
Stuley, V. A.

Свободных экз. нет

Найти похожие

Expression of Ki-67 and CD34 on blood and bone marrow cells of CML patients with different response to imatinib and nilotinib therapy / T. Perekhrestenko [et al.] // Experimental Oncology. - 2020. - Том 42, N 2. - P144-147

MeSH-главная:
ЛЕЙКОЗ МИЕЛОИДНЫЙ ХРОНИЧЕСКИЙ АТИПИЧЕСКИЙ, BCR-ABL ОТРИЦАТЕЛЬНЫЙ -- LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE (кровь, патофизиология)
Аннотация: To assess the expression of Ki-67 protein and CD34 antigen on peripheral blood (PB) and bone marrow (BM) cells in chronic myelogenous leukemia (CML) patients with different response to tyrosine kinase inhibitors (TKI) imatinib (IM) and nilotinib (NI) therapy. Patients and Methods: BM aspirate and PB samples from 41 CML patients treated with IM and NI were studied by cytogenetic, molecular genetic, and flow cytometry methods. According to the response to TKIs, the patients were distributed into the optimal response, warning, and treatment failure groups. Results: The patients with optimal response to TKI therapy showed the lowest levels of Ki-67 expression in PB and BM compared with the patients from warning and falure treatment groups, however, Ki-67 expression was close to the reference values in PB (0.7 ± 0.3)%, only in NI-treated patients, The highest expression of Ki-67 in PB was observed in patients from treatment failure groups. In PB of patients who received NI and did not achieve optimal response, CD34+ cell count increased by almost 4 times compared with that in the optimal response group. The results indicated that CD34+ cell pool expanded in patients with poor response to both IM and NI. In patients with optimal response to NI therapy, CD34+ cell counts in PB were within the reference range and did not exceed 0.5%. Similar results were observed for Ki-67 and CD34+ in BM hematopoietic cells. Conclusions: Ki-67 expression and CD34+ cell count in PB and BM of CML patients increased with the acquisition of clonal resistance to IM and NI. NI provides a deeper molecular response compared with IM
Доп.точки доступа:
Perekhrestenko, T.
Melnyk, U.
Goryainova, N.
Diagil, I.

Свободных экз. нет

Найти похожие

Peculiarities of abnormal karyotypes formation in therapy-related acute leukemias / S. V. Andreieva [et al.] // Experimental Oncology. - 2020. - Том 42, N 2. - P126-129

MeSH-главная:
ЛЕЙКОЗЫ -- LEUKEMIA (генетика)
ГЕНЕТИЧЕСКАЯ ИЗМЕНЧИВОСТЬ -- GENETIC VARIATION (иммунология)
КАРИОТИП -- KARYOTYPE
Аннотация: To determine ways of formation of abnormal karyotypes in two clinical cases of secondary acute leukemias of myeloid and lymphoid lineages. Material and Methods: Bone marrow cells of one patient with therapy-related acute monoblastic/monocytic leukemia and one patient with therapy-related acute lymphoblastic leukemia were examined by cytogenetic GTG banding technique. Results: An unusually large number of quantitative and structural anomalies of chromosomes in therapy-related acute monoblastic/monocytic leukemia have been established, which have many features in common with chromothripsis, namely instability of clones that manifested itself through quantitative anomalies (trisomy, monosomy, marker chromosomes, including chromosome 5), structural — t(9;11), deletions of the long arm of chromosomes 8 and 14, derivatives of chromosomes 3 and 7, ring chromosomes. In case of secondary acute lymphoblastic leukemia, the anomalous clone with balanced translocation in all 20 metaphase plates 46,XX,t(1;15)(p21;q24) has been registered, which is not described in the literature. Therefore, the diagnostic and prognostic value of such anomaly is unknown. Conclusions: Rearrangement with the involvement of the locus 11q23 was recorded in the case of chemotherapy treatment without topoisomerase II inhibitors. The complex karyotype formed after chemotherapy and radiotherapy, which is a criterion for an unfavorable prognosis of the disease, is considered as the equivalent of chromothripsis. t(1;15) is considered as an abnormality that can be attributed to the group of favorable secondary acute lymphoblastic leukemia prognosis
Доп.точки доступа:
Andreieva, S. V.
Kyselova, O. A.
Serbin, I. M.
Alkhimova, O. G.

Свободных экз. нет

Найти похожие

Anti-proliferative effects of a blueberry extract on a panel of tumor cell lines of different origin / H. Lamdan [et al.] // Experimental Oncology. - 2020. - Том 42, N 2. - P101-108

MeSH-главная:
НОВООБРАЗОВАНИЙ КЛЕТКИ КУЛЬТИВИРУЕМЫЕ -- TUMOR CELLS, CULTURED (действие лекарственных препаратов, патология)
ЧЕРНИКА -- HUCKLEBERRY PLANT
Аннотация: Blueberries are among the fruits with the highest antioxidant activity and have been recognized by their health promoting properties. Aim: In vitro study of the anti-proliferative effects of a blueberry extract on a panel of cancer cells from different origin. Materials and Methods: A blueberry extract was produced using ethanol as extracting solvent. The anti-proliferative activity of the extract was evaluated against seven tumor cell lines. The properties of blueberry extract to decrease cell adhesion and migration were also investigated. Results: Blueberry extract showed a dose-dependent inhibitory effect on cell proliferation for all cell lines. Non-cytotoxic concentrations of the extract decreased cell adhesion in five of seven cell lines studied and inhibited the migration of MDA-MB-231 and PC-3 tumor cells. Conclusion: This work provides additional evidence regarding the ability of blueberry extract to inhibit the growth and decrease cell adhesion and migration of different cancer cell lines in vitro
Доп.точки доступа:
Lamdan, H.
Garcia-Lazaro, R. S.
Lorenzo, N.
Galigiuri, L. G.
Alonso, D. F.
Farina, H. G.

Свободных экз. нет

Найти похожие

Nanog as prognostic factor of prostate cancer course / T. V. Zadvornyi [et al.] // Experimental Oncology. - 2020. - Том 42, N 2. - P94-100

MeSH-главная:
ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ НОВООБРАЗОВАНИЯ -- PROSTATIC NEOPLASMS (терапия)
Аннотация: The variability of the clinical course of prostate cancer (PC) indicates the need to find factors that could predict the aggressive potential of neoplasms accounting the biological characteristics of tumor cells. In this context, the role of NANOG, a transcription factor involved in maintaining pluripotency and one of the markers of cancer stem cells (CSCs), is being actively studied today. Aim: To investigate the level of NANOG mRNA in tumor tissue of patients with PC and to analyze the possibility of its use as a marker of the disease course. Materials and Methods: The study involved 85 patients with PC of stages II–IV. Morphological and immunohistochemical studies were performed on serial paraffin sections of resected PC using monoclonal antibodies to Ki-67 and androgen receptor. NANOG and miR-214 mRNA expression in tumor cells was analyzed by real-time reverse transcription polymerase chain reaction. The identification of CSCs was performed by double-labeled immunohistochemical method using primary antibodies to CD24 and CD44. Results: We have revealed notable variability of NANOG mRNA levels in tumor tissue of patients with PC (mean 4.18 ± 0.65 a.u. with individual deviations from 0.11 ± 0.03 a.u. to 15.24 ± 0.36 a.u.). According to NANOG mRNA levels, two groups of the PC patients were delineated: group 1 and group 2, with the average NANOG mRNA levels of 2.12 ± 0.16 a.u., and 8.68 ± 1.24 a.u., respectively. The NANOG mRNA levels in tumor tissue of PC patients of groups 1 and 2 correlated with preoperative serum prostate-specific antigen level (r = 0.58; p 0.05 and r
Доп.точки доступа:
Zadvornyi, T. V.
Lukianova, N. Yu.
Borikun, T. V.
Vitruk, Yu. V.
Stakhovsky, E. O.
Chekhun, V. F.

Свободных экз. нет

Найти похожие

10.

Shvets, Yu. V.
Human microbiota and effectiveness of cancer chemotherapy / Yu. V. Shvets, N. Yu. Lukianova, V. F. Chekhun // Experimental Oncology. - 2020. - Том 42, N 2. - P82-93

MeSH-главная:
НОВООБРАЗОВАНИЯ -- NEOPLASMS (лекарственная терапия, микробиология)
Аннотация: This review presents up-to-date information on the effects of microbiota on the individual chemotherapy sensitivity in cancer treatment. Recent studies have shown that a fine balance between the intestinal microbiota and the immune system is crucial for maintaining an efficacy of cancer chemotherapy. A number of antitumor drugs have complex mechanisms of action involving not only direct effects but also the activity of the intestinal microbiota and the immune system. A unique combination of these factors contributes to the individual chemotherapy sensitivity
Доп.точки доступа:
Lukianova, N. Yu.
Chekhun, V. F.

Свободных экз. нет

Найти похожие

11.

Conjugation of new DNA vaccine with polyethylenimine induces cellular immune response and tumor regression in neuroblastoma mouse model / M. V. Stegantseva [et al.] // Experimental Oncology. - 2020. - Том 42, N 2. - P120-125

MeSH-главная:
НЕЙРОБЛАСТОМА -- NEUROBLASTOMA (иммунология, патофизиология)
Аннотация: To estimate immunogenicity and antitumor effect of new DNA vaccine against neuroblastoma using tyrosine hydroxylase as an antigen and linear polyethylenimine (PEI) 20 kDa as a synthetic DNA carrier in syngeneic mouse tumor model. Materials and Methods: DNA vaccine was made by cloning the tyrosine hydroxylase minigene fused to the potato virus X coat protein gene into the expression vector. The A/J mice were vaccinated by three intramuscular injections. For immunogenicity study, immune response was estimated by target cells cytotoxicity assay, interferon-gamma production in enzyme-linked immunospot assay and antigen-specific antibodies in 14 days after the final vaccination. Antitumor effect was assessed by measurement of tumor volume and event-free survival rate in mice with engrafted NB41A3 murine neuroblastoma cells following three intramuscular injections of the vaccine: 7 days before, 5 and 10 days after tumor engraftment. The immune response was also assessed on the 30th day after tumor engraftment. Results: The immunogenicity and antitumor effect of the vaccine in the form of aqueous solution of DNA and DNA-PEI conjugate were compared. Splenocytes cytotoxicity was the highest in the group of DNA-PEI vaccines (37.3 ± 6.9% lysis of target cells) compared with the unconjugated DNA vaccine (26.2 ± 4.0%) and placebo control (21.9 ± 3.7%). The production of interferon-gamma in the enzyme-linked immunospot assay was about ten times higher in the DNA-PEI group than in the other groups. The vaccine slowed or prevented the growth of the tumor. Mice vaccinated with the DNA-PEI vaccine had significantly better survival compared to control group (p 0.0003). Conclusions: DNA vaccine against tyrosine hydroxylase, administered as a DNA-PEI 20 kDa conjugate, slows down the growth of neuroblastoma cells engrafted to mice
Доп.точки доступа:
Stegantseva, M. V.
Shinkevich, V. A.
Tumar, E. M.
Meleshko, A. N.

Свободных экз. нет

Найти похожие

12.

Expression of micro-RNA hsa-miR-30c-5p and hsa-miR-138-1 in renal cell carcinoma / K. V. Onyshchenko [et al.] // Experimental Oncology. - 2020. - Том 42, N 2. - P115-119

MeSH-главная:
ПОЧЕК НОВООБРАЗОВАНИЯ -- KIDNEY NEOPLASMS (патофизиология)
Аннотация: To analyze the expression levels of hsa-miR-30c-5p and hsa-miR-138-1 in tumors of patients with renal cell carcinoma to determine whether they could be used as diagnostic markers. Materials and Methods: The relative expression of hsa-miR-30c-5p and hsa-miR-138-1 was compared in the paired samples of kidney tumor tissue and conventionally normal tissue adjacent to the tumor. Results: We found a significant decrease in miR-30c-5p and miR-138-1 levels in tumor tissues even in the cases of early stage cancer. In addition, miR-138-1 expression was lower in renal cell carcinoma Fuhrman grade G3 + G4 as compared to Fuhrman grade G2. However, we found no association between miR-30c-5p and miR-138-1 expression in the tumors and the major clinical and pathological characteristics of renal cell carcinoma patients. Conclusions: A significant reduction in the expression levels of hsa-miR-30c-5p and hsa-miR-138-1 in renal cell carcinoma indicates the feasibility of further studies on the probable diagnostic utility of these markers
Доп.точки доступа:
Onyshchenko, K. V.
Voitsitskyi, T. V.
Grygorenko, V. M.
Saidakova, N. O.
Pereta, L. V.
Onyschuk, A. P.
Skrypkina, I. Ya.

Свободных экз. нет

Найти похожие

13.

Antonenko, S. V.
Inhibition of USP1, a new partner of Bcr-Abl, results in decrease of Bcr-Abl level in K562 cells / S. V. Antonenko, G. D. Telegeev // Experimental Oncology. - 2020. - Том 42, N 2. - P109-114

MeSH-главная:
ЛЕЙКОЗ МИЕЛОИДНЫЙ ХРОНИЧЕСКИЙ АТИПИЧЕСКИЙ, BCR-ABL ОТРИЦАТЕЛЬНЫЙ -- LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE (патофизиология)
Аннотация: To analyze interaction of ubiquitin specific peptidase 1 (USP1) with Bcr-Abl and to assess the relation between USP1 functional activity and Bcr-Abl expression in K562 chronic myeloid leukemia cells. Materials and Methods: The interaction between USP1 and Bcr-Abl in K562 cells was analyzed by co-immunoprecipitation, Western blot analysis, and confocal microscopy. Results: A direct interaction between Bcr-Abl oncoprotein and USP1 protein in K562 cells was established by co-immunoprecipitation. Immunofluorescence analysis and confocal microscopy revealed that Bcr-Abl/USP1 protein complex is formed in the cell nucleus. The inhibition of USP1 protein activity by ML323 reduced the level of Bcr-Abl oncoprotein in K562 cells. Conclusions: USP1 protein has been identified as a new protein partner of Bcr-Abl oncoprotein in chronic myeloid leukemia. The relationship between the functional activity of USP1 protein and the level of Bcr-Abl oncoprotein has been demonstrated, suggesting that the targeted inhibition of USP1 activity could be a challenging approach for reducing Bcr-Abl expression
Доп.точки доступа:
Telegeev, G. D.

Свободных экз. нет

Найти похожие

Тематический навигатор

Статистика обращений

© Международная Ассоциация пользователей и разработчиков электронных библиотек и новых информационных технологий
(Ассоциация ЭБНИТ)